Patient dies in a troubled HBV drug program — forcing developers to scrap the drug and shift focus

Things have just gone from bad to worse at Hopkinton, MA-based Spring Bank Pharmaceuticals.

Researchers say that a patient died in their Phase IIb hep B study of inarigivir for hep B — and they’re scrapping the work and shifting focus to STING.